Genomic Insertional Mutagenesis & Oncogenesis Mapping Services for In Vivo CAR

Online Inquiry

Background Service What We Can Offer Workflow Specialty Services Highlights FAQs Contact

Creative Biolabs provides Genomic Insertional Mutagenesis & Oncogenesis Mapping Services for In Vivo CAR to address key safety concerns in gene therapy development, including vector integration behavior, clonal expansion risk, insertion-associated oncogenic activation, and the need for high-resolution genomic safety evidence. This service enables characterization of integration landscapes and the detection of potential genotoxicity signals through high-resolution insertion-site profiling and clonal architecture analysis using Linear Amplification-Mediated PCR (LAM-PCR) combined with advanced sequencing technologies. By integrating genomic mapping with bioinformatics-driven safety assessment, Creative Biolabs supports robust evaluation of insertional risks and translational safety for in vivo CAR programs.

Introduction

Insertional mutagenesis remains a critical safety consideration in integrating gene delivery systems used for CAR engineering. Genomic integration events may influence transcriptional regulation, activate proto-oncogenes, or disrupt tumor suppressor genes, potentially leading to clonal dominance. Recent studies in gene-modified immune cell therapies highlight that integration site preferences and clonal selection contribute significantly to long-term safety outcomes. Therefore, high-resolution mapping of integration landscapes is essential for advancing safe and controllable in vivo CAR technologies.

Our Service

Creative Biolabs provides integration site mapping and oncogenic risk profiling designed for in vivo CAR development and integrating vector systems. Our service enables detailed characterization of vector integration distribution, hotspot identification, and clonal expansion dynamics across target tissues.

Our key deliverables provide essential data for preclinical safety evaluation, vector optimization, and risk mitigation. We deliver genome-wide integration site profiling along with clonal abundance estimation. Our analysis identifies insertion hotspots near regulatory regions and annotates oncogenic risks linked to proto-oncogene proximity. Furthermore, we provide longitudinal tracking of clonal expansion patterns in vivo. These insights combine into a clear integration landscape interpretation that directly supports your regulatory submissions.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Analysis of Genomic Insertional Mutagenesis & Oncogenesis Mapping for In Vivo CAR. (Creative Biolabs Original)

Creative Biolabs delivers multi-layered analytical solutions for integration site characterization and oncogenesis risk assessment. Our core technology platforms include LAM-PCR for high-resolution integration site capture and NGS-based profiling pipelines. We also utilize advanced algorithms for clonal tracking and abundance quantification. Furthermore, our bioinformatics tools handle genome annotation for hotspot mapping and calculate oncogenic proximity scoring systems. Finally, we perform tissue-specific integration distribution analysis in in vivo CAR models.

Our Workflow

Clients will receive a full integration site mapping report, clonal expansion frequency datasets, oncogenic risk annotation with gene-level analysis, together with raw sequencing data and processed bioinformatic files.

Workflow of Genomic Insertional Mutagenesis & Oncogenesis Mapping for In Vivo CAR. (Creative Biolabs Original)

Clients need to provide in vivo CAR vector design details, organ and blood tissue biopsy samples, and experimental metadata covering dosing regimens, sampling timepoints, and animal model specifications.

Specialty Services

LAM-PCR & Target-NGS Golden Standard Integration Site Analysis Services

Utilizing gold-standard LAM-PCR and targeted NGS, this high-resolution service precisely identifies the exact genomic locations of vector integration. It delivers unmatched sensitivity in mapping insertion sites, providing crucial data to ensure the safety and predictability of your cell therapy products.

Learn More →

Genome-Wide Vectorial Randomness Assessment Services

How randomly do your vectors integrate? This unbiased, genome-wide platform evaluates insertion distribution across the entire chromatin landscape, identifying hazardous hotspots and clonal dominance to mitigate insertional mutagenesis risks and satisfy stringent regulatory safety benchmarks.

Learn More →

Pre-Infusion Genomic Baseline Background Profiling Services

Establishing a pristine genetic blueprint before therapy, this screening maps the patient's baseline genomic background, including pre-existing mutations and clonal hematopoiesis. This vital dataset allows clinical developers to accurately differentiate therapy-induced changes from background genetic variations.

Learn More →

Benefits

Customizable study design supporting different vectors, including viral and non-viral integrating systems used in CAR engineering.
Sensitive detection of rare integration events and low-frequency clonal populations across multiple tissue types.
Comprehensive oncogenic risk annotation including proximity to proto-oncogenes, regulatory elements, and tumor suppressor genes.
Quantitative clonal expansion analysis for monitoring dominant integration-driven cell populations over time.

FAQs

Q1: Why is integration site mapping important for in vivo CAR systems?

A1: It provides critical insight into where vectors integrate into the genome, helping assess risks of gene activation or disruption that may affect safety and long-term stability.

Q2: Can this service detect early signs of clonal expansion?

A2: Yes, clonal abundance analysis can identify dominant integration events that may indicate early expansion signals in vivo models.

Q3: Is LAM-PCR suitable for low-frequency integration detection?

A3: LAM-PCR enables sensitive capture of rare integration events, making it suitable for detecting low-abundance clones in complex tissue samples.

Q4: How does this service support regulatory submissions?

A4: It generates structured genomic safety data, including integration profiles and risk annotations, which can support preclinical safety documentation.

Partner with Us

Creative Biolabs delivers high-precision genomic safety assessment solutions tailored for in vivo CAR and integrating vector systems. We combine advanced insertion site profiling, robust bioinformatics, and flexible study design to support both discovery research and preclinical safety evaluation. Our services are fully customizable to match different vector types, tissue models, and study scales, ensuring actionable insights for genomic stability and oncogenic risk control. For detailed project consultation, technical discussion, or customized study design, please reach out to our scientific team.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.